There seems to be DPP-4 inhibitors lower postprandial blood glucose by preventing the rapid degradation of incretins in early-stage T2DM patients who have enough pancreatic insulin reserve [6–8]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.